ClinicalTrials.gg
CompletedNCT00951015ING112276Updated Jan 16, 2018Results posted

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

A Phase 2 interventional study of GSK1349572 and efavirenz in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 35 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.

Read the detailed description

This Phase IIb study in HIV-infected antiretroviral naive adult subjects will include a dose-ranging evaluation of GSK1349572 10mg, 25mg and 50mg once daily blinded doses and a control arm of open label efavirenz 600mg once daily. Background ART for all study subjects will be chosen by the investigators and will be either Truvada or Epzicom/Kivexa. Data from the three doses of GSK1349572 will be compared on the basis of antiviral activity, safety/tolerability and pharmacokinetics over 16-24 weeks.

Several planned interim analyses will evaluate data in real time; any doses considered inferior will be dropped and subjects on those doses of GSK1349572 will have the option to switch to either the highest dose still under investigation or the selected dose. Subjects will be able to remain in the study, unless they reach a stopping criterion, for at least 96 weeks.

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • GSK1349572
  • emtricitabine
  • tenofovir
  • efavirenz
  • abacavir
  • antiretroviral therapy naive
  • dose selection
  • HIV-1 Infection
  • integrase inhibitor
  • HIV infection
  • once daily
  • lamivudine
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 208 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infected male or female adults at least 18 years of age. Women capable of becoming pregnant must use appropriate during the study (as defined by the protocol);
  • HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to 1000copies/mL;
  • greater than or equal to 200cells/mm3 (or higher as local guidelines dictate);
  • ART-naive (less than or equal to 10 days of prior therapy with any antiretroviral agent). Any previous exposure to an HIV integrase inhibitor other than GSK1349572 will be exclusionary.
  • No evidence of viral resistance to any antiretroviral drug indicative of primary transmitted resistance at screening;
  • Able to understand and comply with protocol requirements;
  • Able to provide written prior to screening;
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Note: Subjects starting abacavir as part of the NRTI backbone must have been screened and be negative for the HLA-B*5701 allele.

Exclusion criteria

Exclusion Criteria:

  • Any pre-existing or serious mental or physical disorder which could compromise ability to comply with the protocol or compromise subject safety;
  • Women who are pregnant or breastfeeding;
  • An active AIDS-defining condition at the screening visit;
  • Previous participation in an experimental drug and/or vaccine trial(s) within 30 days or 5 half-lives;
  • History of pancreatitis or hepatitis within the previous 6 months, including positive result. Asymptomatic infection will not be exclusionary, however subject who will require HCV therapy during the trial should be excluded. Any subject with a history of liver cirrhosis with or without hepatitis viral co-infection will be excluded.
  • Any condition which could interfere with the absorption, distribution, metabolism or excretion of the drug;
  • Any acute or Grade 4 laboratory abnormality at screening;
  • History of upper gastrointestinal bleed and/or subjects with active peptic ulcer disease;
  • Estimated \<50 mL/min;
  • (ALT) greater than or equal to 5 times ;
  • Alanine aminotransferase (ALT) greater than or equal to 3xULN and greater than or equal to 1.5xULN (with >35% direct bilirubin);
  • Lipase greater than or equal to 3xULN;
  • \< 100 g/L(10 g/dL);
  • History of allergy to the study drugs or their components or drugs of their class;
  • Treatment with radiation therapy, cytotoxic chemotherapeutic agents, any agents with activity against -1 or immunomodulators within 28 days prior to screening;
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to screening;
  • History of protocol-defined cardiac diseases;
  • Personal or family history of prolonged syndrome;
  • Any clinically significant finding, as specified in the protocol, on electrocardiograph ();
  • Significant blood loss in excess of 500 mL within a 56 day period prior to screening visit;
  • Immunization within 30 days prior to first dose of product;
  • French subjects: The subject has participated in any study using an investigational drug during the previous 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer, prior to screening for the study or the subject will participate simultaneously in another clinical study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    10 mg GSK1349572

    subjects will receive GSK1349572 10mg once daily blinded to dose

    Drug: GSK1349572

  • Experimental
    25mg GSK1349572

    subjects will receive GSK1349572 25mg once daily blinded to dose

    Drug: GSK1349572

  • Experimental
    50mg GSK1349572

    subjects will receive GSK1349572 50mg once daily blinded to dose

    Drug: GSK1349572

  • Other
    efavirenz control

    efavirenz will serve as the internal control arm

    Drug: efavirenz

Interventions

  • investigational HIV-1 integrase inhibitor

  • approved therapy for HIV-1 infection, used as an internal study control

06

What researchers measure

Primary outcomes

  1. Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Week 16. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason. Data are reported per the Week 16 report. In later cuts of the data, the Week 16 values may have changed (because of the nature of the TLOVR algorithm).ITT-E Population included all randomized participants who received at least one dose of study medication

    Time frame: Week 16

Secondary outcomes

  1. Viral Change Over the Initial 2 Weeks of Treatment

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline and Week 2. Viral change is defined as the change in plasma HIV-1 RNA over the initial 2 weeks of treatment, calculated as the value at Week 2 minus the value at Baseline. Only those participants available at the specified time point were analyzed.

    Time frame: Baseline and Week 2

  2. Change From Baseline in HIV-1 RNA at the Indicated Time Points

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

  3. Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at the Indicated Time Points

    Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT-E Population.

    Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

  4. Number of Participants With New HIV-associated Conditions of the Indicated Class

    HIV-associated conditions were assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the acquired immunodeficiency syndrome (AIDS) surveillance case definition.

    Time frame: From Baseline up to Week 96

  5. Number of Participants With the Indicated Type of HIV-1 Disease Progression (AIDS or Death)

    Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CAT A at Baseline (BS) to CAT B event (EV), CAT A at BS to a CAT C EV; CAT B at BS to a CAT C EV; CAT C at BS to a new CAT C EV; or CAT A, B, or C at BS to death.

    Time frame: From Baseline up to Week 96

  6. Number of Participants With Plasma HIV-1 RNA <50 c/mL

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

    Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

  7. Number of Participants With Plasma HIV-1 RNA <400 c/mL

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<400 c/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

    Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

  8. Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Events (SAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. All clinically suspected cases of hypersensitivity reaction to abacavir in participants receiving abacavir/lamivudine were reported as SAEs. Medical or scientific judgment was to have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold \>=3%) and SAEs.

    Time frame: From Baseline up to Week 96/Early Withdrawal

  9. Number of Participants With the Indicated Grade 1 to Grade 4 Treatment-emergent Clinical Chemistry and Hematology Toxicities

    Blood samples were collected for the measurement of clinical chemistry and hematology parameters. Toxicities were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

    Time frame: From Baseline up to Week 96/Early Withdrawal

  10. Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance

    For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Genotypic Resistance Population: all participants in the ITT-E Population with available on-treatment genotypic data, excluding participants who were not protocol-defined virologic failures.

    Time frame: From Baseline up to Week 96/Early Withdrawal

  11. Number of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance

    For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.

    Time frame: From Baseline up to Week 96/Early Withdrawal

  12. Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) at the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance

    The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. Fold increase in DTG FC at the time of PDVF was derived as the PDVF FC/Baseline FC ratio. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Phenotypic Resistance Population: all participants in the ITT-E Population with available on-treatment phenotypic data

    Time frame: From Baseline up to Week 96/Early Withdrawal

  13. Plasma DTG Concentration

    Blood samples for the determination of plasma DTG concentration were collected from the participants randomized to receive DTG, at the following time points: pre-dose and 2-4 hours post-dose at Weeks 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. The Pharmacokinetic (PK) Summary Population is comprised of all participants who received DTG and underwent intensive PK sampling or limited PK sampling during the study and provided evaluable DTG PK parameters. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles).Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.

    Time frame: Week 2, Week 12, and Week 24

  14. AUC(0-tau) of DTG

    The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed.

    Time frame: Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2

  15. Maximal Concentration (Cmax), Minimal Concentration (Cmin), and Concentration at the End of Dosing Interval (Ctau) of DTG

    The Cmax, Cmax, and Ctau of DTG were determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.

    Time frame: Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2

  16. Pre-dose Concentration (C0) and C0 Avg of DTG

    The plasma DTG C0 of DTG was determined using limited/sparse PK sampling at Week 2, Week 12, and Week 24. C0 avg was calculated at Week 24 as the mean of the C0 of DTG at Week 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.

    Time frame: Week 2, Week 12, and Week 24

  17. Time to Maximal Drug Concentration (Tmax) of DTG

    Tmax of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.

    Time frame: Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2

  18. Relationship Between the Change From Baseline in Plasma HIV-1 RNA at Week 2 and the Indicated Plasma DTG PK Parameters

    Relationships between Week 2 plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in plasma HIV-1 RNA at Week 2 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between plasma HIV-1 RNA and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. PK/Pharmacodynamic (PD) Analysis Population: all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable DTG plasma concentration data considered suitable for investigation of relationship with the PD measures

    Time frame: Week 2

  19. Relationship Between the Change From Baseline in CD4+ Cell Counts at Week 96 and the Indicated Plasma DTG PK Parameters

    Relationships between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], C0avg \[average pre-dose concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in CD4+ cell counts at Week 96 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between CD4+ cell counts and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association.Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.Only those participants available at the specified time points were analyzed (represented by n=X in the category titles)

    Time frame: Week 96

  20. Relationship Between the Indicated Safety Parameters at Week 96 and the Indicated Plasma DTG PK Parameters

    Relationships between log-transformed plasma DTG PK parameters (AUC\[0-tau\], Cmax, C0, C0avg, Ctau, and Cmin) and safety parameters (AE occurrence, maximum AE intensity, alanine aminotransferase \[ALT\], change from Baseline \[CFB\] in ALT, total bilirubin, CFB in total bilirubin, creatine kinase, CFB in creatine kinase, triglycerides, CFB in triglycerides, lipase, CFB in lipase, total cholesterol \[TC\], CFB in TC) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between safety parameters and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. The presence of \>=1 AE was used for AE occurrence. The most severe AE grade/intensity was used for maximum AE intensity. Maximum laboratory values per participant were used for safety parameters. CFB was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Week 96

  21. Relationship Between Gastrointestinal System Organ Class AEs of Special Interest at Week 96 and the Indicated Plasma DTG PK Parameters

    Logistic regressions were performed to examine the correlation between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], Ctau \[concentration at the end of the dosing interval\], and C0avg \[average pre-dose concentration\]) on log scales and the presence of gastrointestinal system organ class AEs (abdominal pain, diarrhea, nausea, and vomiting) at Week 96. Data are presented as estimates from logistic regression, which is a measure of the association between AEs of special interest and plasma DTG PK parameters. A value of 0 indicates no statistical association; a large absolute value of the estimate indicates higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Results are presented for participants in any DTG group (overall DTG).Only those participants available at the specified time points were analyzed represented by n=X in the category titles

    Time frame: Week 96

Other outcomes

  1. Change From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at the Indicated Time Points

    Change from Baseline in CD8+ cell count data are not available; CD8+ data are only listed on a per-participant basis and were not summarized.

    Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

07

Results

Posted Nov 11, 2013

Participant flow

Randomization Phase participants received Dolutegravir (DTG 10, 25 or 50 milligrams\[mg\]) with Placebo/Efavirenz (EFV) for 96 Weeks . DTG participants who completed 96 Weeks continued or were switched to receive DTG 50 mg in Open label phase until DTG was locally available.

Randomization Phase 96 Week
Participant flow — Randomization Phase 96 Week
MilestoneDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDOpen-label DTG 50 mg QD
Started535151500
Completed484446400
Not completed575100
Withdrew: Adverse event11250
Withdrew: Lack of efficacy11000
Withdrew: Protocol violation11100
Withdrew: Protocol-defined stopping criteria00010
Withdrew: Lost to follow-up03120
Withdrew: Withdrawal by subject21120
Open-label Phase
Participant flow — Open-label Phase
MilestoneDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDOpen-label DTG 50 mg QD
Started0000138
Completed000088
Not completed000050
Withdrew: Adverse event00003
Withdrew: Lack of efficacy00001
Withdrew: Protocol violation000012
Withdrew: Lost to follow-up000012
Withdrew: Withdrawal by subject000014
Withdrew: Physician decision00008

Outcome measures

PrimaryNumber of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16

Plasma samples were collected for quantitative HIV-1 RNA analysis at Week 16. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason. Data are reported per the Week 16 report. In later cuts of the data, the Week 16 values may have changed (because of the nature of the TLOVR algorithm).ITT-E Population included all randomized participants who received at least one dose of study medication

Time frame:
Week 16
Reported as:
Number · participants
Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16
participantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 1651474629
SecondaryViral Change Over the Initial 2 Weeks of Treatment

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline and Week 2. Viral change is defined as the change in plasma HIV-1 RNA over the initial 2 weeks of treatment, calculated as the value at Week 2 minus the value at Baseline. Only those participants available at the specified time point were analyzed.

Time frame:
Baseline and Week 2
Reported as:
Mean · Log10 c/mL
Viral Change Over the Initial 2 Weeks of Treatment
Log10 c/mLDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Viral Change Over the Initial 2 Weeks of Treatment-2.387 ± 0.4595-2.365 ± 0.5458-2.392 ± 0.4241-1.930 ± 0.4312
SecondaryChange From Baseline in HIV-1 RNA at the Indicated Time Points

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Reported as:
Mean · Log10 c/mL
Change From Baseline in HIV-1 RNA at the Indicated Time Points
Log10 c/mLDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Week 1, n=53, 50, 48, 50-1.815 ± 0.3999-1.773 ± 0.4650-1.738 ± 0.3840-1.562 ± 0.4158
Week 2, n=53, 50, 50, 48-2.387 ± 0.4595-2.365 ± 0.5458-2.392 ± 0.4241-1.930 ± 0.4312
Week 4, n=53, 50, 50, 45-2.629 ± 0.5863-2.583 ± 0.6337-2.713 ± 0.5471-2.162 ± 0.5400
Week 8, n=52, 50, 49, 45-2.657 ± 0.6980-2.666 ± 0.6667-2.848 ± 0.6556-2.450 ± 0.5989
Week 12, n=53, 49, 49, 45-2.685 ± 0.6831-2.671 ± 0.6850-2.860 ± 0.6772-2.603 ± 0.5869
Week 16, n=52, 49, 49, 45-2.718 ± 0.6593-2.668 ± 0.6826-2.859 ± 0.6876-2.698 ± 0.6715
Week 20, n=52, 48, 49, 44-2.701 ± 0.6423-2.662 ± 0.6908-2.869 ± 0.6896-2.745 ± 0.6602
Week 24, n=52, 49, 48, 45-2.700 ± 0.6261-2.657 ± 0.6969-2.853 ± 0.6889-2.773 ± 0.7026
Week 32, n=52, 49, 47, 45-2.717 ± 0.6588-2.658 ± 0.6991-2.855 ± 0.6963-2.772 ± 0.7021
Week 40, n=51, 48, 47, 44-2.647 ± 0.7039-2.665 ± 0.7051-2.855 ± 0.6934-2.795 ± 0.7169
Week 48, n=51, 48, 48, 45-2.723 ± 0.6519-2.667 ± 0.6934-2.850 ± 0.6849-2.711 ± 0.7765
Week 60, n=50, 48, 48, 44-2.741 ± 0.6444-2.675 ± 0.7012-2.825 ± 0.7458-2.765 ± 0.7035
Week 72, n=51, 47, 48, 44-2.742 ± 0.6453-2.622 ± 0.8052-2.860 ± 0.6930-2.757 ± 0.7094
Week 84, n=51, 47, 47, 43-2.725 ± 0.6506-2.670 ± 0.7064-2.855 ± 0.6923-2.743 ± 0.7321
Week 96, n=48, 44, 46, 39-2.728 ± 0.6494-2.680 ± 0.7116-2.854 ± 0.7061-2.807 ± 0.7238
SecondaryChange From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at the Indicated Time Points

Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT-E Population.

Time frame:
Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Reported as:
Median · Cells per cubic millimeter
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at the Indicated Time Points
Cells per cubic millimeterDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Week 1, n=53, 50, 48, 5085.0 (18.0 to 134.0)94.5 (40.0 to 160.0)75.5 (18.5 to 129.5)42.5 (-23.0 to 111.0)
Week 2, n=53, 50, 50, 4775.0 (37.0 to 124.0)79.0 (27.0 to 138.0)99.5 (53.0 to 160.0)55.0 (-10.0 to 132.0)
Week 4, n=53, 50, 50, 4575.0 (34.0 to 151.0)89.0 (36.0 to 165.0)110.0 (46.0 to 170.0)89.0 (30.0 to 165.0)
Week 8, n=52, 50, 49, 44118.5 (65.5 to 210.5)156.5 (93.0 to 226.0)129.0 (105.0 to 201.0)104.5 (34.5 to 240.5)
Week 12, n=53, 48, 48, 45139.0 (96.0 to 284.0)137.5 (61.0 to 250.0)171.5 (107.5 to 269.0)127.0 (58.0 to 186.0)
Week 16, n=52, 49, 49, 44153.0 (95.0 to 276.0)176.0 (86.0 to 227.0)160.0 (94.0 to 227.0)115.5 (65.5 to 226.0)
Week 20, n=52, 48, 49, 44163.5 (79.5 to 288.5)200.0 (103.0 to 316.5)139.0 (64.0 to 238.0)136.0 (54.5 to 215.5)
Week 24, n=51, 49, 47, 44159.0 (97.0 to 233.0)206.0 (102.0 to 289.0)167.0 (125.0 to 268.0)109.5 (66.0 to 229.0)
Week 32, n=50, 48, 47, 44221.5 (94.0 to 300.0)195.5 (109.0 to 294.0)203.0 (125.0 to 282.0)146.5 (82.5 to 223.5)
Week 40, n=50, 48, 47, 44205.0 (136.0 to 364.0)204.5 (157.5 to 346.5)224.0 (123.0 to 322.0)171.5 (123.0 to 268.0)
Week 48, n=51, 47, 47, 45204.0 (127.0 to 384.0)249.0 (143.0 to 416.0)223.0 (141.0 to 292.0)174.0 (91.0 to 292.0)
Week 60, n=51, 48, 47, 43265.0 (173.0 to 365.0)278.0 (198.5 to 369.5)229.0 (166.0 to 306.0)221.0 (153.0 to 355.0)
Week 72, n=51, 47, 48, 44236.0 (177.0 to 351.0)285.0 (186.0 to 427.0)220.0 (146.0 to 373.0)195.0 (144.0 to 334.5)
Week 84, n=51, 47, 46, 42292.0 (222.0 to 408.0)313.0 (244.0 to 366.0)280.0 (197.0 to 379.0)296.5 (187.0 to 400.0)
Week 96, n=48, 44, 46, 39335.0 (253.5 to 478.5)391.5 (243.0 to 527.0)326.0 (236.0 to 451.0)301.0 (204.0 to 445.0)
SecondaryNumber of Participants With New HIV-associated Conditions of the Indicated Class

HIV-associated conditions were assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the acquired immunodeficiency syndrome (AIDS) surveillance case definition.

Time frame:
From Baseline up to Week 96
Reported as:
Number · Participants
Number of Participants With New HIV-associated Conditions of the Indicated Class
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Category B2011
Category C0010
Death1000
SecondaryNumber of Participants With the Indicated Type of HIV-1 Disease Progression (AIDS or Death)

Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CAT A at Baseline (BS) to CAT B event (EV), CAT A at BS to a CAT C EV; CAT B at BS to a CAT C EV; CAT C at BS to a new CAT C EV; or CAT A, B, or C at BS to death.

Time frame:
From Baseline up to Week 96
Reported as:
Number · Participants
Number of Participants With the Indicated Type of HIV-1 Disease Progression (AIDS or Death)
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
CAT A at Baseline to a CAT C event0000
CAT B at Baseline to a CAT C event0010
CAT C at Baseline to a new CAT C event0000
CAT A, B, or C at Baseline to death1000
SecondaryNumber of Participants With Plasma HIV-1 RNA <50 c/mL

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

Time frame:
Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Reported as:
Number · Participants
Number of Participants With Plasma HIV-1 RNA <50 c/mL
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Baseline0000
Week 16443
Week 22219116
Week 43735319
Week 846454318
Week 1250464525
Week 1651464729
Week 2051474738
Week 2451464741
Week 3250454643
Week 4049454642
Week 4848454640
Week 6048444641
Week 7248444540
Week 8447434638
Week 9642404536
SecondaryNumber of Participants With Plasma HIV-1 RNA <400 c/mL

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<400 c/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

Time frame:
Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Reported as:
Number · Participants
Number of Participants With Plasma HIV-1 RNA <400 c/mL
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Baseline0000
Week 125201615
Week 245454123
Week 452494832
Week 852494941
Week 1252494945
Week 1652484945
Week 2052484945
Week 2452474845
Week 3252474845
Week 4050474845
Week 4850474844
Week 6050464844
Week 7250464743
Week 8450454742
Week 9646434639
SecondaryNumber of Participants With Any Adverse Event (AE) and Any Serious Adverse Events (SAE)

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. All clinically suspected cases of hypersensitivity reaction to abacavir in participants receiving abacavir/lamivudine were reported as SAEs. Medical or scientific judgment was to have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold \>=3%) and SAEs.

Time frame:
From Baseline up to Week 96/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Events (SAE)
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Any AE50464646
Any SAE5577
SecondaryNumber of Participants With the Indicated Grade 1 to Grade 4 Treatment-emergent Clinical Chemistry and Hematology Toxicities

Blood samples were collected for the measurement of clinical chemistry and hematology parameters. Toxicities were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

Time frame:
From Baseline up to Week 96/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With the Indicated Grade 1 to Grade 4 Treatment-emergent Clinical Chemistry and Hematology Toxicities
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Alanine amino transferase711319
Cholesterol18161324
Creatinine kinase17675
Lipase1113119
Triglycerides0121
Alkaline phosphatase10110
Amylase2314
Aspartate amino transferase12869
Carbon dioxide content/bicarbonate28242330
Creatinine0400
Hypercalcemia0001
Hyperglycaemia16151717
Hyperkalemia0011
Hypernatremia1110
Hypocalcemia4558
Hypoglycaemia3354
Hypokalemia4133
Hyponatremia612713
Low-density lipoprotein cholesterol14151120
Magnesium7654
Phosphate, inorganic9151411
Total bilirubin3430
Activated partial thromboplastin time71265
Hemoglobin0101
International normalized ratio6965
Platelet count1411
Prothrombin time7874
Total neutrophils97610
White blood cell count1111
SecondaryNumber of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance

For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Genotypic Resistance Population: all participants in the ITT-E Population with available on-treatment genotypic data, excluding participants who were not protocol-defined virologic failures.

Time frame:
From Baseline up to Week 96/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
A23A/V10—0
S255N10—0
SecondaryNumber of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance

For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.

Time frame:
From Baseline up to Week 96/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Number of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance10—0
SecondaryNumber of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) at the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance

The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. Fold increase in DTG FC at the time of PDVF was derived as the PDVF FC/Baseline FC ratio. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Phenotypic Resistance Population: all participants in the ITT-E Population with available on-treatment phenotypic data

Time frame:
From Baseline up to Week 96/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) at the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance
ParticipantsDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
<1 fold01——
1-<2 fold20——
2-<4 fold00——
4-<8 fold00——
>=8 fold00——
SecondaryPlasma DTG Concentration

Blood samples for the determination of plasma DTG concentration were collected from the participants randomized to receive DTG, at the following time points: pre-dose and 2-4 hours post-dose at Weeks 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. The Pharmacokinetic (PK) Summary Population is comprised of all participants who received DTG and underwent intensive PK sampling or limited PK sampling during the study and provided evaluable DTG PK parameters. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles).Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.

Time frame:
Week 2, Week 12, and Week 24
Reported as:
Mean · Micrograms per milliliter (µg/mL)
Plasma DTG Concentration
Micrograms per milliliter (µg/mL)DTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Week 2, Pre-dose, n=46, 44, 43, 00.3580 ± 0.183210.6779 ± 0.440851.4044 ± 0.88041—
Week 2, 2-4 hours post-dose, n=31, 29, 29, 01.0121 ± 0.281251.9716 ± 0.718903.8414 ± 1.87405—
Week 12, Pre-dose, n= 46, 45, 44, 00.3648 ± 0.167910.5759 ± 0.326451.4169 ± 1.00152—
Week 12, 2-4 hours post-dose, n=48, 45, 45, 01.0374 ± 0.275171.7907 ± 0.709533.6056 ± 1.33862—
Week 24, Pre-dose, n=45, 44, 44, 00.3766 ± 0.233990.6636 ± 0.507671.4534 ± 0.94283—
Week 24, 2-4 hours post-dose, n=45, 45, 45, 01.0113 ± 0.340831.9021 ± 0.794303.5397 ± 1.36538—
SecondaryAUC(0-tau) of DTG

The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed.

Time frame:
Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2
Reported as:
Geometric mean · Hours*µg/mL
AUC(0-tau) of DTG
Hours*µg/mLDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
AUC(0-tau) of DTG16.0 ± 4023.1 ± 4848.1 ± 40—
SecondaryMaximal Concentration (Cmax), Minimal Concentration (Cmin), and Concentration at the End of Dosing Interval (Ctau) of DTG

The Cmax, Cmax, and Ctau of DTG were determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.

Time frame:
Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2
Reported as:
Geometric mean · µg/mL
Maximal Concentration (Cmax), Minimal Concentration (Cmin), and Concentration at the End of Dosing Interval (Ctau) of DTG
µg/mLDTG 10 mg ODDTG 25 mg ODDTG 50 mg ODEFV 600 mg OD
Cmax1.10 ± 371.71 ± 433.40 ± 27—
Cmin0.33 ± 640.44 ± 680.94 ± 74—
Ctau0.37 ± 550.45 ± 711.05 ± 72—
SecondaryPre-dose Concentration (C0) and C0 Avg of DTG

The plasma DTG C0 of DTG was determined using limited/sparse PK sampling at Week 2, Week 12, and Week 24. C0 avg was calculated at Week 24 as the mean of the C0 of DTG at Week 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.

Time frame:
Week 2, Week 12, and Week 24
Reported as:
Geometric mean · Microgram per milliliter (µg/mL)
Pre-dose Concentration (C0) and C0 Avg of DTG
Microgram per milliliter (µg/mL)DTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
C0, Week 2, n=46, 44, 43, 00.31 ± 580.57 ± 621.20 ± 61—
C0, Week 12, n=46, 45, 44, 00.33 ± 490.47 ± 771.13 ± 95—
C0, Week 24, n=45, 44, 44, 00.33 ± 670.57 ± 741.20 ± 74—
C0 avg, n=48, 46, 46, 00.34 ± 490.56 ± 611.25 ± 55—
SecondaryTime to Maximal Drug Concentration (Tmax) of DTG

Tmax of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.

Time frame:
Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2
Reported as:
Median · Hours
Time to Maximal Drug Concentration (Tmax) of DTG
HoursDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QD
Time to Maximal Drug Concentration (Tmax) of DTG2.0 (2.0 to 4.0)2.0 (2.0 to 8.0)2.0 (1.9 to 4.0)—
SecondaryRelationship Between the Change From Baseline in Plasma HIV-1 RNA at Week 2 and the Indicated Plasma DTG PK Parameters

Relationships between Week 2 plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in plasma HIV-1 RNA at Week 2 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between plasma HIV-1 RNA and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. PK/Pharmacodynamic (PD) Analysis Population: all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable DTG plasma concentration data considered suitable for investigation of relationship with the PD measures

Time frame:
Week 2
Reported as:
Number · Pearson's correlation coefficient
Relationship Between the Change From Baseline in Plasma HIV-1 RNA at Week 2 and the Indicated Plasma DTG PK Parameters
Pearson's correlation coefficientDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDOverall DTG
AUC(0-tau)0.426-0.018-0.258—-0.086
Cmax0.452-0.051-0.150—-0.055
Ctau0.273-0.100-0.263—-0.129
SecondaryRelationship Between the Change From Baseline in CD4+ Cell Counts at Week 96 and the Indicated Plasma DTG PK Parameters

Relationships between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], C0avg \[average pre-dose concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in CD4+ cell counts at Week 96 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between CD4+ cell counts and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association.Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.Only those participants available at the specified time points were analyzed (represented by n=X in the category titles)

Time frame:
Week 96
Reported as:
Number · Pearson's correlation coefficient
Relationship Between the Change From Baseline in CD4+ Cell Counts at Week 96 and the Indicated Plasma DTG PK Parameters
Pearson's correlation coefficientDTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDOverall DTG
AUC(0-tau), n=13, 14, 15, 0-0.1000.3790.008—-0.005
Cmax, n=13, 14, 15, 0-0.0470.3320.234—0.037
C0avg, n=43, 40, 42, 0-0.009-0.0130.206—-0.011
Ctau, n=13, 14, 15, 0-0.2890.299-0.074—-0.055
SecondaryRelationship Between the Indicated Safety Parameters at Week 96 and the Indicated Plasma DTG PK Parameters

Relationships between log-transformed plasma DTG PK parameters (AUC\[0-tau\], Cmax, C0, C0avg, Ctau, and Cmin) and safety parameters (AE occurrence, maximum AE intensity, alanine aminotransferase \[ALT\], change from Baseline \[CFB\] in ALT, total bilirubin, CFB in total bilirubin, creatine kinase, CFB in creatine kinase, triglycerides, CFB in triglycerides, lipase, CFB in lipase, total cholesterol \[TC\], CFB in TC) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between safety parameters and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. The presence of \>=1 AE was used for AE occurrence. The most severe AE grade/intensity was used for maximum AE intensity. Maximum laboratory values per participant were used for safety parameters. CFB was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Week 96
Reported as:
Number · Pearson's correlation coefficient
Relationship Between the Indicated Safety Parameters at Week 96 and the Indicated Plasma DTG PK Parameters
Pearson's correlation coefficientOverall DTG
AUC(0-tau) versus AE occurrence, n=450.114
AUC(0-tau) versus maximum AE intensity, n=450.171
AUC(0-tau) versus ALT, n=45-0.196
AUC(0-tau) versus CFB in ALT, n=45-0.201
AUC(0-tau) versus total bilirubin, n=450.364
AUC(0-tau) versus CFB in total bilirubin, n=450.147
AUC(0-tau) versus creatine kinase, n=45-0.168
AUC(0-tau) versus CFB in creatine kinase, n=45-0.145
AUC(0-tau) vs Triglycerides, n=450.104
AUC(0-tau) versus CFB in triglycerides, n=450.216
AUC(0-tau) versus lipase, n=45-0.066
AUC(0-tau) versus CFB in lipase, n=450.092
AUC(0-tau) versus total cholesterol, n=45-0.097
AUC(0-tau) versus CFB in total cholesterol, n=45-0.153
Cmax versus AE occurrence, n=450.061
Cmax versus maximum AE intensity, n=450.110
Cmax versus ALT, n=45-0.135
Cmax versus CFB in ALT, n=45-0.135
Cmax versus total bilirubin, n=450.265
Cmax versus CFB in total bilirubin, n=450.033
Cmax versus creatine kinase, n=45-0.188
Cmax versus CFB in creatine kinase, n=45-0.161
Cmax versus triglycerides, n=450.134
Cmax versus CFB in triglycerides, n=450.244
Cmax versus lipase, n=45-0.034
Cmax versus CFB in lipase, n=450.115
Cmax versus total cholesterol, n=45-0.101
Cmax versus CFB in total cholesterol, n=45-0.192
C0 versus AE occurrence, n=133-0.080
C0 versus maximum AE intensity, n=133-0.003
C0 versus ALT, n=133-0.196
C0 versus CFB in ALT, n=133-0.237
C0 versus total bilirubin, n=1330.298
C0 versus CFB in total bilirubin, n=1330.120
C0 versus creatine kinase, n=133-0.094
C0 versus CFB in creatine kinase, n=133-0.093
C0 versus triglycerides, n=133-0.058
C0 versus CFB in triglycerides, n=133-0.012
C0 versus lipase, n=133-0.187
C0 versus CFB in lipase, n=133-0.137
C0 versus total cholesterol, n=133-0.179
C0 versus CFB in total cholesterol, n=133-0.125
C0avg versus AE occurrence, n=140-0.028
C0avg versus maximum AE intensity, n=1400.036
C0avg versus ALT, n=140-0.166
C0avg versus CFB in ALT, n=140-0.177
C0avg versus total bilirubin, n=1400.319
C0avg versus CFB in total bilirubin, n=1400.109
C0avg versus creatine kinase, n=140-0.114
C0avg versus CFB in creatine kinase, n=140-0.110
C0avg versus triglycerides, n=1400.057
C0avg versus CFB in triglycerides, n=1400.092
C0avg versus lipase, n=140-0.164
C0avg versus CFB in lipase, n=140-0.120
C0avg versus total cholesterol, n=140-0.170
C0avg versus CFB in total cholesterol, n=140-0.083
Ctau versus AE occurrence, n=450.190
Ctau versus maximum AE intensity, n=450.205
Ctau versus ALT, n=45-0.281
Ctau versus CFB in ALT, n=45-0.285
Ctau versus total bilirubin, n=450.446
Ctau versus CFB in total bilirubin, n=450.237
Ctau versus creatine kinase, n=45-0.143
Ctau versus CFB in creatine kinase, n=45-0.125
Ctau versus triglycerides, n=450.061
Ctau versus CFB in triglycerides, n=450.172
Ctau versus lipase, n=45-0.131
Ctau versus CFB in lipase, n=450.056
Ctau versus total cholesterol, n=45-0.039
Ctau versus CFB in total cholesterol, n=45-0.108
Cmin versus AE occurrence, n=450.156
Cmin versus maximum AE intensity, n=450.193
Cmin versus ALT, n=45-0.236
Cmin versus CFB in ALT, n=45-0.253
Cmin versus total bilirubin, n=450.430
Cmin versus CFB in total bilirubin, n=450.171
Cmin versus creatine kinase, n=45-0.132
Cmin versus CFB in creatine kinase, n=45-0.124
Cmin versus triglycerides, n=45-0.042
Cmin versus CFB in triglycerides, n=450.057
Cmin versus lipase, n=45-0.135
Cmin versus CFB in lipase, n=450.032
Cmin versus total cholesterol, n=45-0.194
Cmin versus CFB in total cholesterol, n=45-0.208
SecondaryRelationship Between Gastrointestinal System Organ Class AEs of Special Interest at Week 96 and the Indicated Plasma DTG PK Parameters

Logistic regressions were performed to examine the correlation between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], Ctau \[concentration at the end of the dosing interval\], and C0avg \[average pre-dose concentration\]) on log scales and the presence of gastrointestinal system organ class AEs (abdominal pain, diarrhea, nausea, and vomiting) at Week 96. Data are presented as estimates from logistic regression, which is a measure of the association between AEs of special interest and plasma DTG PK parameters. A value of 0 indicates no statistical association; a large absolute value of the estimate indicates higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Results are presented for participants in any DTG group (overall DTG).Only those participants available at the specified time points were analyzed represented by n=X in the category titles

Time frame:
Week 96
Reported as:
Number · estimated effect
Relationship Between Gastrointestinal System Organ Class AEs of Special Interest at Week 96 and the Indicated Plasma DTG PK Parameters
estimated effectOverall DTG
Abdominal pain versus AUC(0-tau), n=45-2.49
Abdominal pain versus Cmax, n=45-2.98
Abdominal pain versus Ctau, n=45-1.72
Abdominal pain versus C0avg, n=140-0.41
Diarrhoea versus AUC(0-tau), n=45-0.62
Diarrhoea versus Cmax, n=45-0.98
Diarrhoea versus Ctau, n=45-0.29
Diarrhoea versus C0avg, n=1400.13
Nausea versus AUC(0-tau), n=45-0.31
Nausea versus Cmax, n=45-0.72
Nausea versus Ctau, n=450.03
Nausea versus C0avg, n=140-0.32
Vomiting versus AUC(0-tau), n=45-1.29
Vomiting versus Cmax, n=45-1.61
Vomiting versus Ctau, n=45-1.15
Vomiting versus C0avg, n=140-0.89
Other pre-specifiedChange From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at the Indicated Time Points

Change from Baseline in CD8+ cell count data are not available; CD8+ data are only listed on a per-participant basis and were not summarized.

Time frame:
Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

No measurements were reported for this outcome.

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected in the time period from Baseline up to end of study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG 10mg QD2/53 (3.8%)6/53 (11.3%)49/53 (92.5%)
DTG 25mg QD0/51 (0%)4/51 (7.8%)46/51 (90.2%)
DTG 50mg QD0/51 (0%)7/51 (13.7%)45/51 (88.2%)
EFV 600mg0/50 (0%)7/50 (14%)46/50 (92%)
Open-label DTG 50 mg QD2/138 (1.4%)16/138 (11.6%)112/138 (81.2%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventDTG 10mg QDDTG 25mg QDDTG 50mg QDEFV 600mgOpen-label DTG 50 mg QD
Device malfunctionProduct Issues0/530/510/511/501/138
BronchitisInfections and infestations0/530/510/511/500/138
DepressionPsychiatric disorders0/530/510/511/500/138
EpididymitisInfections and infestations0/530/510/511/500/138
GastroenteritisInfections and infestations0/530/510/511/500/138
HydrocephalusNervous system disorders0/530/510/511/500/138
NeurosyphilisInfections and infestations0/530/510/511/500/138
Suicide attemptPsychiatric disorders0/530/510/511/500/138
PneumoniaInfections and infestations0/530/511/510/501/138
Wrist fractureInjury, poisoning and procedural complications0/530/511/510/501/138
Most frequent other events
Showing 10 of 426
Most frequent other events
EventDTG 10mg QDDTG 25mg QDDTG 50mg QDEFV 600mgOpen-label DTG 50 mg QD
DizzinessNervous system disorders2/533/513/5111/502/138
NauseaGastrointestinal disorders10/538/516/517/502/138
DiarrhoeaGastrointestinal disorders6/539/517/515/5012/138
HeadacheNervous system disorders7/536/518/513/508/138
Viral upper respiratory tract infectionInfections and infestations7/537/516/515/5020/138
InsomniaPsychiatric disorders0/537/516/516/505/138
RashSkin and subcutaneous tissue disorders5/533/512/516/502/138
FatigueGeneral disorders2/534/512/516/503/138
CoughRespiratory, thoracic and mediastinal disorders5/534/516/512/5010/138
DepressionPsychiatric disorders3/536/512/515/506/138

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDTotal
Mean34.2 ± 9.2537.0 ± 9.7937.0 ± 8.8940.7 ± 11.1937.2 ± 10.00
Sex: Female, Male
Sex: Female, Male(Participants)DTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDTotal
Female1156628
Male42464544177
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)DTG 10 mg QDDTG 25 mg QDDTG 50 mg QDEFV 600 mg QDTotal
African American/African Heritage (HER)768425
American Indian or Alaska Native134210
Japanese/East Asian HER/South East Asian HER00011
Native Hawaiian or other Pacific Islander30003
White41423843164
African American/African HER & White00101
Asian & White10001
08

Study locations

35 sites
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Denver, Colorado 80209, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33306, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Santa Fe, New Mexico 87505, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Lyon cedex 04, 69317, France
  • GSK Investigational Site
    Montpellier Cedex 5, 34295, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Paris Cedex 10, 75475, France
  • GSK Investigational Site
    Paris Cedex 13, 75651, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Frankfurt, Hessen 60311, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Bergamo, Lombardia 24127, Italy
  • GSK Investigational Site
    Brescia, Lombardia 25123, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Smolensk, 214006, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 190103, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196645, Russian Federation
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
09

References and documents

Publications

  • van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012 Feb;12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0. Epub 2011 Oct 20. PubMed 22018760 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Feb 2010 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 3 years 8 months after primary completion. A results delay was requested in Mar 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2009
First posted
Aug 3, 2009
Start
Jul 30, 2009
Primary completionActual
Feb 26, 2010
CompletionActual
Dec 22, 2016
Results delay requested
Mar 17, 2011
Results first posted
Nov 11, 2013
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00951015
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Aug 3, 2009
Start date
Jul 30, 2009
Primary completion
Feb 26, 2010
Completion
Dec 22, 2016
Results posted
Nov 11, 2013
Last update
Jan 16, 2018

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion